Recombinant Human IGFBP-3 Protein, CF


There are currently no images for IGFBP-3 (675-B3).

Every product we sell is backed by Novus' 100% Guarantee. If you have used this product, please submit your images and reviews to earn reward points.

Product Details

Reactivity HuSpecies Glossary
Applications Bioactivity

Order Details

Recombinant Human IGFBP-3 Protein, CF Summary

Details of Functionality
Measured by its ability to inhibit the biological activity of IGF-I or IGF-II on MCF‑7 human breast cancer cells. Karey, K.P. et al. (1988) Cancer Research 48:4083. The ED50 for this effect is 0.05-0.15 µg/mL in the presence of 14 ng/mL Recombinant Human IGF‑II (Catalog # 292-G2).
Mouse myeloma cell line, NS0-derived human IGFBP-3 protein
Gly28-Lys291, with an N-terminal Met
Accession #
N-terminal Sequence
Protein/Peptide Type
Recombinant Proteins
>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
Endotoxin Note
<0.01 EU per 1 μg of the protein by the LAL method.


Theoretical MW
29 kDa.
Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
37-47 kDa, reducing conditions
Read Publications using
675-B3 in the following applications:

Packaging, Storage & Formulations

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
Lyophilized from a 0.2 μm filtered solution in Acetonitrile and TFA.
>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
Reconstitution Instructions
Reconstitute at 100 μg/mL in sterile PBS.


This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human IGFBP-3 Protein, CF

  • acid stable subunit of the 140 K IGF complex
  • binding protein 29
  • binding protein 53
  • growth hormone-dependent binding protein
  • IBP-3
  • IBP3BP-53
  • IGF-binding protein 3
  • IGFBP3
  • IGFBP-3
  • insulin-like growth factor binding protein 3
  • insulin-like growth factor-binding protein 3


Insulin-like growth factor binding protein-3 (IGFBP-3) is one of six members of the insulin­like growth factor (IGF) binding protein superfamily which function to modulate the biological activity of IGF (1). Human IGFBP-3 is the major binding protein of IGF where it exists in circulation as a ternary complex with the acid-labile subunit (ALS) (2). Like other IGFBP members, human IGFBP-3 includes a cysteine-rich C-terminal domain, a highly variable central linker domain, and another
N-terminal cysteine-­rich domain (2, 3). Human IGFBP­-3 cDNA encodes a 291 amino acid (aa) precursor protein with a 27 aa signal peptide that is processed to generate the 264 aa mature protein. Mature human IGFBP-3 shares 82% aa sequence identity with both mouse and rat IGFBP-3. Post-­translational glycosylation and phosphorylation of IGFBP-3 modifies the affinities of the binding protein. Proteolysis of IGFBP-3 by tissue plasminogen activator (tPA), a disintegrin and metaloproteases (ADAMs), and prostate specific antigen (PSA) contributes to IGFBP-3 degradation or a reduction in its affinity for IGF (4-6). The majority of soluble IGFBP-3 found in circulation is secreted from hepatic non-parenchymal cells. IGFBP-3 expression can be modulated by p53 as well as by various cytokines and growth factors (7, 8). In addition to its role in stabilizing and transporting circulating IGF, IGFBP-3 has been shown to potentiate EGF-EGFR-mediated cell growth through the activation of sphingosine kinase1 (SPHK1) and sphingosin-1-phosphate (S1P) (9, 10). IGFBP-3 has also been shown to modulate adipogenesis (11). Binding of IGFBP-3 to non-IGF-related ligands has been shown to regulate TGF-beta signaling, DNA damage, apoptosis, autophagy, and gene transcription (12). Interactions with non-IGF-related ligands is thought to contribute, in part, to the dichotomous stimulatory and inhibitory effects of IGFBP-3 on cell growth (2).

  1. Shimasaki, S. and N. Ling (1991) Prog. Growth Factor Res. 3:243.
  2. Baxter, R.C. (2013) J. Cell Commun. Signal 7:179.
  3. Baxter, R.C. (2014) Nat. Rev. Cancer 14:329.
  4. Mochizuki, S. et al. (2004) Biochem. Biophys. Res. Commun. 315:79.
  5. Cohen, P. et al. (1994) J. Endocrinol. 142:407.
  6. Bang, P. (1995) Prog. Growth Factor Res. 6:285.
  7. Perks, C.M. and J.M. Holly (2008) J. Mammary Gland Biol. Neoplasia 13:455.
  8. Chan, K. and E.M. Spencer (1997) Endocrine 7:95.
  9. Guix, M. et al. (2008) J. Clin. Invest. 118:2609.
  10. Martin, J.L. et al. (2009) J. Biol. Chem. 284:25542.
  11. Chan, S.S. et al. (2009) Am. J. Physiol. Endocrinol. Metab. 296:E654.
  12. Martin, J.L. and R.C. Baxter (2011) Growth Factors 29:235.

Customers Who Viewed This Item Also Viewed...

Species: Hu, Mu, Rt
Applications: WB, ELISA, IHC, Neut
Species: Hu, Mu, Rt
Applications: WB, ELISA, IHC, Neut
Species: Hu, Mu, Po, Bv, Rb
Applications: WB, Flow, ICC/IF, IHC-Fr, IHC-P, IP, PAGE
Species: Hu
Applications: WB, Simple Western, Neut
Species: Hu, Mu
Applications: WB, ICC/IF, IHC, IHC-P
Species: Hu
Applications: WB, IHC
Species: Mu
Applications: WB, IHC
Species: Mu
Applications: WB
Species: Hu, Mu, Rt, Bv
Applications: WB, IHC-P
Species: Hu
Applications: WB, ELISA(Cap), ELISA(Det), ELISA(Sta)
Species: Hu, Mu
Applications: WB, Flow, IHC, ELISA(Cap), ELISA(Det), ICC, Neut, ELISA(Sta)

Publications for IGFBP-3 (675-B3)(9)

We have publications tested in 2 confirmed species: Human, Mouse.

We have publications tested in 2 applications: Bioassay, EnzAct.

Filter By Application
All Applications
Filter By Species
All Species
Showing Publications 1 - 9 of 9.
Publications using 675-B3 Applications Species
Matthew N Svalina IGF1R as a Key Target in High Risk, Metastatic Medulloblastoma Sci Rep, 2016;6(0):27012. 2016 [PMID: 27255663] (Bioassay, Human) Bioassay Human
Elzi, David J, Lai, Yanlai, Song, Meihua, Hakala, Kevin, Weintraub, Susan T, Shiio, Yuzuru Plasminogen activator inhibitor 1--insulin-like growth factor binding protein 3 cascade regulates stress-induced senescence. Proc Natl Acad Sci U S A, 2012;109(30):12052-7. 2012 [PMID: 22778398] (Bioassay, Human) Bioassay Human
Bogatkevich GS, Ludwicka-Bradley A, Highland KB, Hant F, Nietert PJ, Singleton CB, Feghali-Bostwick CA, Silver RM Impairment of the antifibrotic effect of hepatocyte growth factor in lung fibroblasts from African Americans: possible role in systemic sclerosis. Arthritis Rheum., 2007;56(7):2432-42. 2007 [PMID: 17599773] (Bioassay, Human) Bioassay Human
Rosendahl AH, Forsberg G IGF-I and IGFBP-3 augment transforming growth factor-beta actions in human renal carcinoma cells. Kidney Int., 2006;70(9):1584-90. 2006 [PMID: 16969385] (Bioassay, Human) Bioassay Human
Schnapp LM, Donohoe S, Chen J, Sunde DA, Kelly PM, Ruzinski J, Martin T, Goodlett DR Mining the acute respiratory distress syndrome proteome: identification of the insulin-like growth factor (IGF)/IGF-binding protein-3 pathway in acute lung injury. Am. J. Pathol., 2006;169(1):86-95. 2006 [PMID: 16816363] (Bioassay, Human) Bioassay Human
Cortesio CL, Jiang W Mannan-binding lectin-associated serine protease 3 cleaves synthetic peptides and insulin-like growth factor-binding protein 5. Arch. Biochem. Biophys., 2006;449(1):164-70. 2006 [PMID: 16554018] (EnzAct, Human) EnzAct Human
Nakamura M, Miyamoto S, Maeda H, Ishii G, Hasebe T, Chiba T, Asaka M, Ochiai A Matrix metalloproteinase-7 degrades all insulin-like growth factor binding proteins and facilitates insulin-like growth factor bioavailability. Biochem. Biophys. Res. Commun., 2005;333(3):1011-6. 2005 [PMID: 15964556] (EnzAct, Human) EnzAct Human
Congote LF, DiFalco MR, Gibbs BF Thrombospondin 1, produced by endothelial cells under the action of erythropoietin, stimulates thymidine incorporation into erythroid cells and counteracts the inhibitory action of insulin-like growth factor binding protein 3. Cytokine, 2005;30(5):248-53. 2005 [PMID: 15927849] (Bioassay, Human) Bioassay Human
Kirman I, Poltoratskaia N, Sylla P, Whelan RL Insulin-like growth factor-binding protein 3 inhibits growth of experimental colocarcinoma. Surgery, 2004;136(2):205-9. 2004 [PMID: 15300181] (Bioassay, Mouse) Bioassay Mouse

Reviews for IGFBP-3 (675-B3) (0)

There are no reviews for IGFBP-3 (675-B3). By submitting a review you will receive an Amazon e-Gift Card or Novus Product Discount.
  • Review with no image -- $10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen
  • Review with an image -- $25/€18/£15/$25 CAD/¥150 Yuan/¥2500 Yen
  • 1st to review with an image -- $50/€35/£30/$50 CAD/¥300 Yuan/¥5000 Yen

FAQs for IGFBP-3 (675-B3) (0)

There are no specific FAQs related to this product. Read our general customer & technical service FAQs.

Customers Who Bought This Also Bought

Contact Information

Product PDFs


Concentration Calculator

The concentration calculator allows you to quickly calculate the volume, mass or concentration of your vial. Simply enter your mass, volume, or concentration values for your reagent and the calculator will determine the rest.


Review this Product

Be the first to review our Recombinant Human IGFBP-3 Protein, CF and receive a gift card or discount.


Gene Symbol IGFBP3